News
Catalyst throws lifeline to Santhera with $90m Duchenne deal
Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc
